This risk is particularly high when treated with TNF-alpha inhibitors because TNF alpha plays a critical role in the immune mechanism against Mycobacterium tuberculosis.2,3 On the other hand, although biologic agents targeting IL-12/23 and IL-17 seem to be associated with a lower risk of developing active TB, long term data is still limited.4 Here, TNF is linked to tuberculosis.